Vaxart price target lowered to $1.50 from $6 at B. Riley

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart to $1.50 from $6 and keeps a Neutral rating on the shares. The target drop reflects a more conservative estimate of ramp-up of Norovirus and peak market penetration from 35% to 24%, Mamtani tells investors in a research note.